Direct Digital Stock Falls On Q4 Results: Here’s Why

Direct Digital Holdings reported quarterly losses of 8 cents per share which missed the analyst consensus estimate of earnings of 26 cents.

Direct Digital Holdings (NASDAQ:DRCT) shares are dropping after the company reported its fourth-quarter financial results after the bell Tuesday. Here’s a look at the details. 

The Details: Direct Digital Holdings reported quarterly losses of 8 cents per share which missed the analyst consensus estimate of earnings of 26 cents.

The company reported quarterly sales of $41.01 million which missed the analyst consensus estimate of $65.95 million by 37.81% and represented a 33.4% increase over sales of $30.74 million from the same period last year.

“2023 was another transformational year for Direct Digital Holdings, achieving remarkable year-over-year revenue growth of 76% as well as dramatic operational expansion, and impressive results for our shareholders,” commented Mark D. Walker, CEO of Direct Digital.

“Although performance in the fourth quarter was not as strong as we initially expected due to proactive measures we are taking in the face of changing macro industry trends, we are confident our company is in a position to build on the successes of 2023, expand on emerging channel and inorganic growth opportunities and continue our strong revenue growth and market share gains in 2024,” added Walker.

Outlook: The company expects fiscal year 2024 revenue to be in the range of $170 million to $190 million, representing 15% year-over-year growth at the mid-point.

“We are pleased to announce our fiscal year 2024 revenue guidance of $170 million to $190 million. This range demonstrates our belief that we can continue our growth and operational optimization strategies to deliver strong performance for our shareholders this year,” Diana Diaz, CFO, said.

DRCT Price Action: According to Benzinga Pro, Direct Digital shares are down 33.04% after-hours at $17.75 at the time of publication Tuesday.

Related News: What’s Going On With MicroStrategy Stock?

Photo: Pete Linforth from Pixabay

Total
0
Shares
Related Posts
Read More

Can Prison Stocks Break The Shackles And Rally Amid Trump’s Potential Arrest This Tuesday?

Prison stocks are underperforming in the current market recovery, with three major publicly-traded ones trading deep in the red in the year to date. This marks a reversal from 2022, when the stocks notched spectacular gains despite the broader market swoon.

CXW

Read More

Ocuphire Pharma Announces First Patient Enrolled In LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) For The Treatment Of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery

LYNX-2 Follows SPA Agreement with FDA Development of PS is Funded by Ocuphire's Partner ViatrisFARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage

OCUP